RxDoctor Payments Data

Joel Kline, MD

Pulmonary Disease · Iowa City, IANPI 1871584201

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,250 of the $5,104 with a category attached, or 63.7%. GSK accounts for 63.7% of it on its own, with 1 other manufacturer making up the rest.

$5,104in general payments, 2019–2025

Across 9 payments — averaging $567.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • Astrazeneca UK Limited$2K
$105,754in research payments, 2019–2025

Across 13 payments — averaging $8134.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$33K
  • Genentech, Inc.$32K
  • Regeneron$20K
  • GSK$17K
  • Boston Scientific$4K

What the payments were for

  • Consulting fees$3,25064%
  • Travel & lodging$1,53430%
  • Food & beverage$3206%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK1$3,250
Astrazeneca UK Limited8$1,854

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,104 in reported general payments places this provider in the 65th percentile of 110 pulmonary disease providers in Iowa.

See all pulmonary disease providers in Iowa

Medicare billing

Part B allowed, 2024
$56,865
Medicare patients
308
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter145$107,654
NucalaMepolizumab16$57,155
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$29,146
Advair HfaFluticasone Propion/Salmeterol33$12,815
Breo ElliptaFluticasone/Vilanterol17$11,614
Incruse ElliptaUmeclidinium Bromide20$8,034
SymbicortBudesonide/Formoterol Fumarate17$5,269
Fluticasone Propionate HfaFluticasone Propionate20$3,549
Albuterol Sulfate HfaAlbuterol Sulfate112$3,531
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$2,878
Ventolin HfaAlbuterol Sulfate20$1,266
Azithromycin36$685
Montelukast Sodium35$181
Pantoprazole Sodium11$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$3,250$213,603250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 110 pulmonary disease providers in Iowa.

Other pulmonary disease in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →